LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Aggressive Bladder Cancers May Be Identified by Measuring Two Urinary Proteins

By LabMedica International staff writers
Posted on 08 Mar 2015
Print article
British cancer researchers have found that measuring the urinary proteins epidermal growth factor receptor (EGFR) and epithelial cell adhesion molecule (EpCAM) may represent a simple and useful approach for diagnosing and treating patients with the most aggressive bladder cancers.

Investigators at the University of Birmingham (United Kingdom) used shotgun proteomics to identify proteins released into culture media by eight bladder cancer cell lines. This technique starts with the proteins in the mixture being digested, and the resulting peptides separated by liquid chromatography. Tandem mass spectrometry is then used to identify the peptides.

Data obtained by the shotgun proteomics procedure were compared with protein expression data from the Human Protein Atlas. EGFR was identified as a candidate biomarker and measured by ELISA in urine from 60 non-cancer control subjects and from 436 patients with bladder cancer and long-term clinical follow-up.

Results revealed that bladder cancer cell lines shed soluble EGFR ectodomain. Soluble EGFR was also detectable in urine and was highly elevated in some patients with high-grade bladder cancer. Urinary EGFR was an independent indicator of poor bladder cancer-specific survival. In multivariable models including both urinary EGFR and EpCAM, both biomarkers were predictive of bladder cancer-specific survival and had prognostic value over and above that provided by standard clinical observations. Higher levels of the biomarkers correlated with more aggressive cases of cancer and those with poorest rate of survival.

Senior author Dr. Douglas Ward, a senior research fellow at the University of Birmingham, said, "There is an urgent need for prognostic biomarkers that could guide patient management. If such a test could be delivered, in a noninvasive way, it could make treatment much more efficient and that can only be a good thing."

The study was published in the February 26, 2015, online edition of the British Journal of Cancer.

Related Links:

University of Birmingham


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more